Advisory Council On The Misuse Of Drugs
Details
In 2022 the Advisory Council on the Misuse of Drugs (ACMD) was commissioned to give advice on the appropriate classification and scheduling of the synthetic cannabinoid receptor agonist (SCRA) Cumyl-PeGaClone under the Misuse of Drugs Act 1971. Cumyl-PeGaClone was added to schedule II of the Convention on Psychotropic Substances of 1971 during the 64th Commission on Narcotic Drugs (CND) meeting in April 2021.
The ACMD has therefore written this report describing the use and harms of Cumyl-PeGaClone and other recently encountered SCRA and has provided recommendations on their classification and scheduling.
We are aware this publication may have accessibility issues. We are reviewing it so that we can fix these. Read more about our accessible documents policy.